| Literature DB >> 34335779 |
Masoumeh Beig1, Mohammad Taheri1, Mohammad Reza Arabestani1,2.
Abstract
In recent years, the prevalence of carbapenem-resistant Pseudomonas aeruginosa isolates has become a worldwide concern. Rapid and accurate detection of carbapenemase-producing P. aeruginosa isolates is so important. The aim of this study was to evaluate the performance of the phenotypic methods such as Modified Hodge test (MHT), CarbaNP (CNPt), combined double-disk synergy test (CDDT), and carbapenem inactivation method (CIM) for rapid and accurate detection of clinical carbapenemase production of P. aeruginosa isolates. This study was performed on 97 P. aeruginosa strains, which were isolated from clinical samples in Hamadan hospitals, western Iran in 2017-2018. Antibiotic susceptibility testing was performed using disk diffusion and minimum inhibitory concentration (MIC) by E-test method. We evaluated the performance of MHT, CarbaNP, CDDT, and CIM tests in comparison to polymerase chain reaction (PCR) for the detection of carbapenemase-producing isolates. Additionally, the presence of carbapenem-resistant genes was investigated using the PCR method. Our findings showed that the highest resistance was to cefoxitin (94.8%). Moreover, among the carbapenem antibiotics, the highest resistance was to imipenem (49.4%). Among the 49 carbapenem-resistant isolates, 42 (85.7%) isolates were MIC positive. The results of phenotypic tests showed that CarbaNP, CIM, CDDT, and MHT tests were positive in (48/49, 97.95%), (46/49, 93.87%), (27/49, 57.44%), and (25/49, 53.19%) of isolates, respectively. CarbaNP and CIM tests showed high sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) compared to PCR in P. aeruginosa isolates. CarbaNP and CIM tests are highly sensitive and specific tests for identifying carbapenemase-producing P. aeruginosa isolates.Entities:
Year: 2021 PMID: 34335779 PMCID: PMC8313346 DOI: 10.1155/2021/5582615
Source DB: PubMed Journal: Int J Microbiol
PCR primers for the detection of carbapenemase genes.
| Carbapenemase genes | Sequence (5′–3′) | Primer | Expected amplicon size (bp) | Reference |
|---|---|---|---|---|
| IMP | Imp-F | GGA ATA GAG TGG CTT AAY TCT C | 188 | [ |
| Imp-R | CCA AAC YAC TAS GTT ATC T | |||
| VIM | Vim-F | GAT GGT GTT TGG TCG CAT A | 390 | [ |
| Vim-R | CGA ATG CGC AGC ACC AG | |||
| GIM-1 | GIM-1F | TCG ACA CAC CTT GGT CTG AA | 271 | [ |
| GIM-2R | AAC TTC CAA CTT TGC CAT GC | |||
| SPM-1 | SPM-1F | AAA ATC TGG GTA CGC AAA CG | 477 | [ |
| SPM-1R | ACA TTA TCC GCT GGA ACA GG | |||
| SIM-1 | Sim-1F | TAC AAG GGA TTC GGC ATC G | 570 | [ |
| Sim-1R | TAA TGG CCT GTT CCC ATG TG | |||
| KPC 1-5 | KPC-1F | CATTCAAGGGCTTTCTTGCTGC | 538 | [ |
| KPC-1R | ACGACGGCATAGTCATTTGC | |||
| AMPC | AMPC-F | CGGCTCGGTGAGCAAGACCTTC | 218 | [ |
| AMPC-R | AGTCGCGGATCTGTGCCTGGTC | |||
| OXA-48 | OXA-48-F | GCTTGATCGCCCTCGATT | 281 | [ |
| OXA-48-R | GATTTGCTCCGTGGCCGAAA |
The results of antibiogram testing for P. aeruginosa isolate.
| Antibiotic | No. resistant (%) | Intermediate | Sensitive | Total |
|---|---|---|---|---|
| Piperacillin | 42 (43.3) | 13 (13.4) | 42 (43.3) | 97 |
| Piperacillin/tazobactam | 38 (39.2) | 11 (11.3) | 48 (49.4) | 97 |
| Ceftazidime | 40 (41.2) | 6 (6.2) | 51 (52.6) | 97 |
| Aztreonam | 50 (51.5) | 19 (19.5) | 28 (28.9) | 97 |
| Amikacin | 40 (41.2) | 10 (10.3) | 47 (48.5) | 97 |
| Ciprofloxacin | 53 (54.6) | 2 (2.1) | 42 (43.3) | 97 |
| Meropenem | 40 (41.2) | 5 (5.2) | 52 (53.6) | 97 |
| Doripenem | 45 (46.4) | 2 (2.1) | 50 (51.5) | 97 |
| Cefoxitin | 92 (94.8) | 1 (1) | 4 (4.1) | 97 |
| Tetracycline | 53 (54.6) | 5 (5.2) | 39 (40.2) | 97 |
| Ceftriaxone | 65 (67) | 18 (18.6) | 14 (14.43) | 97 |
| Imipenem | 48 (49.4) | 1 (1) | 48 (49.4) | 97 |
Results of MIC and different phenotypic tests for carbapenemase genes.
| Gene related to carbapenem resistance | MIC imipenem | CDDT | MHT | CIM | CarbaNP |
|---|---|---|---|---|---|
| KPC | >32 | 6/11 | 5/11 | 11/11 | 11/11 |
| IMP | 8 to >32 | 13/20 | 15/20 | 20/20 | 20/20 |
| VIM | 8 to >32 | 10/19 | 14/19 | 19/19 | 19/19 |
| AMPC | 8 to>32 | 16/25 | 14/25 | 22/25 | 24/25 |
| OXA-48 | 8 to>32 | 20/35 | 18/35 | 33/35 | 34/35 |
| SIM | 8 to >32 | 3/8 | 4/8 | 8/8 | 8/8 |
| SPM | 16 | 10/17 | 11/17 | 17/17 | 17/17 |
| GIM | 8 | 3/6 | 3/6 | 6/6 | 6/6 |
| KPC + IMP + AMPC | 8 to >32 | 2/2 | 2/2 | 2/2 | 2/2 |
| KPC + AMPC + OXA-48 | 16 | 2/3 | 1/3 | 3/3 | 3/3 |
| IMP + VIM + OXA-48 | 8 | 3/6 | 6/6 | 6/6 | 6/6 |
| IMP + AMPC + OXA-48 | >32 | 3/5 | 4/5 | 4/5 | 5/5 |
| IMP + KPC + OXA-48 | >32 | 1/1 | 1/1 | 1/1 | 1/1 |
| VIM + KPC + AMPC | >32 | 1/3 | 3/3 | 3/3 | 3/3 |
| VIM + KPC + AMPC + OXA-48 | 8 | 0/1 | 1/1 | 1/1 | 1/1 |
| IMP + VIM + AMPC | 4–8 | 2/4 | 4/4 | 4/4 | 4/4 |
| KPC + OXA-48+VIM + AMPC | >32 | 1/1 | 1/1 | 1/1 | 1/1 |
| IMP + AMPC | 8 | 8/11 | 8/11 | 11/11 | 11/11 |
| VIM + KPC | 16 | 3/5 | 4/5 | 5/5 | 5/5 |
| Not detected | <0.25-2 | 44/48 | 45/48 | 48/48 | 48/48 |
Demographic characteristics of evaluated P. aeruginosa isolates and antibiogram resistance with three main antibiotics.
| Characteristics | No. examined | Imipenem resistance | Meropenem resistance | Doripenem resistance | |||
|---|---|---|---|---|---|---|---|
| No. (%) |
| No. (%) |
| No. (%) |
| ||
|
| |||||||
| 0–10 | 9 | 5 (55.6) | 0.308 | 5 (55.6) | 0.441 | 5 (55.6) | 0.346 |
| 11–20 | 9 | 5 (55.6) | 5 (55.6) | 5 (55.6) | |||
| 21–30 | 7 | 4 (57.1) | 3 (42.8) | 3 (42.8) | |||
| 31–40 | 7 | 3 (42.8) | 2 (28.6) | 2 (28.6) | |||
| 41–50 | 21 | 9 (42.8) | 9 (42.8) | 9 (42.8) | |||
| 51–60 | 14 | 5 (35.7) | 4 (28.6) | 3 (21.4) | |||
| 61–70 | 19 | 13 (68.4) | 12 (63.1) | 13 (68.4) | |||
| 71–80 | 5 | 2 (40) | 2 (40) | 3 (60) | |||
| 81–90 | 5 | 2 (40) | 2 (40) | 3 (60) | |||
| 91–100 | 1 | 1 (100) | 1 (100) | 1 (100) | |||
| Total no. |
|
|
|
| |||
|
| |||||||
|
| |||||||
| Male | 70 | 34 (48.6) | 0.232 | 33 (47.1) | 0.488 | 34 (48.6) | 0.345 |
| Female | 27 | 15 (55.6) | 12 (44.4) | 13 (48.1) | |||
| Total no. |
|
|
|
| |||
|
| |||||||
|
| |||||||
| Burn | 28 | 19 (67.8) | 0.223 | 19 (67.8) | 0.170 | 18 (64.3) | 0.154 |
| Surgery | 5 | 2 (40) | 1 (20) | 0 (0) | |||
| Pulmonary | 11 | 5 (45.4) | 4 (36.4) | 3 (27.3) | |||
| Neurology | 3 | 0 (0) | 1 (33.3) | 1 (33.3) | |||
| Orthopedics | 1 | 0 (0) | 0 (0) | 1 (100) | |||
| Trauma | 13 | 7 (53.8) | 5 (38.4) | 6 (46.1) | |||
| NICU | 8 | 2 (25) | 1 (12.5) | 1 (12.5) | |||
| ICU | 14 | 9 (64.3) | 8 (57.1) | 10 (71.4) | |||
| Hematology | 2 | 1 (50) | 0 (0) | 1 (50) | |||
| Infected | 12 | 4 (33.3) | 6 (50) | 6 (50) | |||
| Total no. |
|
|
|
| |||
|
| |||||||
|
| |||||||
| BC | 22 | 14 (63.6) | 12 (54.5) | 12 (54.5) | |||
| UC | 12 | 3 (25) | 0.082 | 4 (33.3) | 0.401 | 4 (33.3) | 0.243 |
| TC | 33 | 16 (48.5) | 14 (42.4) | 15 (45.4) | |||
| TA | 5 | 3 (60) | 3 (60) | 4 (80) | |||
| Wound | 15 | 9 (60) | 7 (46.7) | 8 (53.3) | |||
| Sputum | 6 | 2 (33.3) | 3 (50) | 2 (33.3) | |||
| CSF | 2 | 0 (0) | 0 (0) | 0 (0) | |||
| Fluid | 1 | 1 (100) | 1 (100) | 1 (100) | |||
| TT | 1 | 1 (100) | 1 (100) | 1 (100) | |||
| Total no. |
|
|
|
| |||
|
| |||||||
|
| |||||||
| 0-10 days | 56 | 20 (35.7) | 18 (32.1) | 14 (25) | |||
| 11-29 days | 25 | 16 (64) | 13 (52) | 18 (72) | |||
| 1-2 months | 16 | 13 (81.2) | 0.433 | 14 (87.5) | 0.455 | 15 (93.7) | 0.601 |
| Total no. |
|
|
|
| |||
Results of sensitivity, specificity, NPV, PPV in CarbaNP versus CIM test.
| No. | CarbaNP | No. | CIM | MIC | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | PPV | NPV | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | ||||
| A | 11/11 | 100 | 100 | 100 | 100 | 11/11 | 100 | 100 | 100 | 100 | >32 |
| B | 40/40 | 100 | 100 | 100 | 100 | 39/40 | 97 | 100 | 100 | 88 | 8 to.32 |
| C | 24/25 | 96 | 100 | 100 | 96 | 22/25 | 89 | 100 | 100 | 88 | 8 to.32 |
| D | 34/35 | 97 | 100 | 100 | 93 | 33/35 | 94 | 100 | 100 | 87 | 8 to.32 |
| IMP | 20/20 | 100 | 100 | 100 | 100 | 20/20 | 100 | 100 | 100 | 100 | 8 to.32 |
| VIM | 19/19 | 100 | 100 | 100 | 100 | 19/19 | 100 | 100 | 100 | 100 | 8 to.32 |
| SIM | 8/8 | 100 | 100 | 100 | 100 | 8/8 | 100 | 100 | 100 | 100 | 8 to.32 |
| SPM | 17/17 | 100 | 100 | 100 | 100 | 17/17 | 100 | 100 | 100 | 100 | 8 to.32 |
| GIM | 21/21 | 100 | 100 | 100 | 100 | 21/21 | 100 | 100 | 100 | 100 | 8 to.32 |
NPV: negative predictive values. PPV: positive predictive values.
Results of sensitivity, specificity, NPV, and PPV in MHT versus IMP.EDTA test.
| No. | MHT | No. | IMP.EDTA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | PPV | NPV | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |||
| A | 5/11 | 64 | 95 | 84 | 86 | 6/11 | 68 | 88 | 68 | 88 |
| B | 23/40 | 70 | 97 | 97 | 34 | 22/40 | 68 | 90 | 97 | 33 |
| C | 14/25 | 69 | 96 | 96 | 68 | 16/25 | 73 | 88 | 89 | 72 |
| D | 18/35 | 67 | 93 | 97 | 45 | 20/35 | 70 | 87 | 94 | 48 |
| IMP | 15/20 | 80 | 93 | 90 | 85 | 13/20 | 74 | 87 | 83 | 80 |
| VIM | 14/19 | 79 | 93 | 90 | 85 | 10/19 | 67 | 88 | 82 | 76 |
| SIM | 4/8 | 66 | 95 | 80 | 91 | 3/8 | 61 | 87 | 57 | 89 |
| SPM | 11/17 | 73 | 93 | 89 | 84 | 10/17 | 70 | 88 | 80 | 82 |
| GIM | 11/21 | 67 | 93 | 91 | 73 | 12/21 | 70 | 87 | 84 | 75 |
NPV: negative predictive values. PPV: positive predictive value.